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Abstract
Background: Among men who have sex with men (MSM) in the UK, an estimated 28% have never tested for HIV
and only 27% of those at higher risk test at least every 6 months. HIV self-testing (HIVST), where the person takes
their own blood/saliva sample and processes it themselves, offers the opportunity to remove many structural and
social barriers to testing. Although several randomised controlled trials are assessing the impact of providing HIVST
on rates of HIV testing, none are addressing whether this results in increased rates of HIV diagnoses that link to
clinical care. Linking to care is the critical outcome because it is the only way to access antiretroviral treatment
(ART). We describe here the design of a large, internet-based randomised controlled trial of HIVST, called SELPHI,
which aims to inform this key question.
Methods/design: The SELPHI study, which is ongoing is promoted via social networking website and app advertising,
and aims to enroll HIV negative men, trans men and trans women, aged over 16 years, who are living in England and
Wales. Apart from the physical delivery of the test kits, all trial processes, including recruitment, take place online. In a
two-stage randomisation, participants are first randomised (3:2) to receive a free baseline HIVST or no free baseline
HIVST. At 3 months, participants allocated to receive a baseline HIVST (and meeting further eligibility criteria) are
subsequently randomised (1:1) to receive the offer of regular (every 3 months) free HIVST, with testing reminders,
versus no such offer. The primary outcome from both randomisations is a laboratory-confirmed HIV diagnosis,
ascertained via linkage to a national HIV surveillance database.
Discussion: SELPHI will provide the first reliable evidence on whether offering free HIVST via the internet increases
rates of confirmed HIV diagnoses and linkage to clinical care. The two randomisations reflect the dual objectives of
detecting prevalent infections (possibly long-standing) and the more rapid diagnosis of incident HIV infections. It is
anticipated that the results of SELPHI will inform future access to HIV self-testing provision in the UK.
Trial registration: DOI 10.1186/ISRCTN20312003 registered 24/10/2016.
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Background
The United Nations (UN) 90–90-90 targets aim by 2020,
that 90% of all people living with HIV (PLWH) are diag-
nosed, that 90% of people diagnosed with HIV are on
ART, and that 90% of those on ART have a suppressed
viral load [1]. The first target (90% diagnosis) remains
the key challenge with global estimates of 47% of PLWH
being unaware of their infection. Knowledge of one’s
own HIV status and accessing ART benefits health on
both an individual and population level. People who are
unaware of their status are estimated to contribute dis-
proportionally to new transmissions (between 60 and
80%) [2]. In the 2017 PHE (Public Health England) re-
port on HIV, it was estimated that 10% of gay/bisexual
men who have sex with men (MSM) were unaware of
their HIV status. Although this percentage has decreased
since 2010, testing is often less frequent than current
recommendations. For example, UK guidelines [3] cur-
rently recommend annual HIV testing for MSM, and
three-monthly testing for those considered ‘at higher
risk’ (a definition that includes condomless (CL) anal sex
with a new partner, diagnosis of new STI or chemsex
drug use). In UK MSM, an estimated 28% have never
tested for HIV and only a quarter of men at ‘higher risk’
of HIV infection test even 6-monthly (27%) [4–6]. Late
diagnosis of HIV also remains a problem in the UK; 32%
of all MSM diagnosed with HIV in 2016 (663/2,096) had
CD4 counts below 350 mm3, which is associated with
greater morbidity and mortality than those who are diag-
nosed earlier in the course of infection. All guidelines
now recommend that PLWH commence ART at diagno-
sis as this has been shown to be beneficial to individual
health even at high CD4 counts [7].
HIV diagnoses in MSM in London have fallen since
2016 and this is thought to be a combination of in-
creased rates of HIV testing, rapid initiation of ART
when HIV is diagnosed (which reduces transmission risk
through sex to almost zero) and increasing use of
pre-exposure prophylaxis (PrEP) [8]. Rates of HIV diag-
nosis in MSM outside London have also reduced but to
a lesser degree [9]. Expanding ways for MSM to test for
HIV outside of traditional settings (such as GUM clinics)
has been a focus for over a decade and there is now a
national self-sampling service. This involves an individ-
ual taking their own test sample which they post back to
the relevant laboratory for testing and are subsequently
contacted with the result.
A further approach is to offer HIV self-testing (HIVST)
where the person not only takes their own blood/saliva
sample but also processes it themselves using a self-testing
kit, and obtains the results immediately. A potential ad-
vantage of HIVST is that, removing structural and social
barriers to testing and increasing associated privacy and
convenience, may lead to increased testing [10, 11].
HIVST is also an opportunity for prevention synergies
with the availability of PrEP (which requires frequent test-
ing), and for harm reduction strategies, such as sexual
partner screening. The WHO now incorporate HIVST
into its global HIV testing guidelines as a ‘supplementary’
or ‘additional’ option [12] and has described it as “an
empowering and innovative way to help achieve the first
of the United Nations 90–90–90 treatment targets” [13].
HIVST also has a number of potential challenges, al-
though empirical data are lacking. Firstly, a person who
has a reactive HIVST requires confirmatory HIV testing
to link to care which relies on the individual seeking
more traditional testing as a gateway to care and sup-
port. It remains unknown what proportion of individuals
who obtain a reactive result on HIVST link to care in a
timely manner [14]. A further issue may be the potential
for social and emotional harms from a reactive test in
the absence of counselling, or coercion to test from a
partner. HIVST may also be a missed opportunity for
STI screening and advice about risk management due to
fewer visits to GUM clinic settings, which may put
MSM at increased risk of other STIs. HIVST kit accur-
acy is also an area of concern, as the window period is
prolonged in comparison to 4th generation tests (anti-
body and P24 antigen test) and the sensitivity is rela-
tively low, particularly with oral fluid HIVST in early
infection or in breakthrough infections on tenofovir-
based PrEP as antibody levels may be low. This is par-
ticularly important during early infection, when the risk
of onward transmission is markedly increased.
Existing evidence base
Evidence suggests that HIVST is acceptable to MSM
and other key populations at risk of HIV globally both in
high and low-income settings [10, 15, 16]. However, des-
pite the theoretical benefits of HIVST, there are limited
European data exploring potential HIVST acceptability,
as well as the values and preferences of MSM or trans
people at risk of HIV infection on the potential impacts
of self-testing approaches in the UK [17–19]. There is
also a lack of evidence on whether HIVST increases
rates of HIV diagnosis in populations at risk of HIV. It is
also unknown whether it is cost-effective for the NHS to
provide free or subsidised HIVST kits. Observational
studies, using follow-up surveys, have documented the
number of self-reported reactive tests as a proportion of
the number of HIVST kits sent out [20]. However, there
is likely to be selection bias in those responding to sur-
veys and it is not known how many individuals would
have sought and obtained their HIV diagnosis through
another testing modality.
There are four on-going or recently reported RCTs of
HIVST in MSM in high resource settings (three in the
US and one in Australia) [21–24]. All use self-reported
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frequency of testing as the primary outcome comparing
HIVST to standard of care. These studies therefore do
not address the key question of whether provision of
HIVST can increase rates of HIV diagnoses that link to
clinical care, which is the gateway to ART. We describe
here the design of a large, internet-based randomised
controlled trial of HIVST, which aims to inform this
question.
Rationale
The primary aim of SELPHI is to measure the impact of
HIVST on new confirmed HIV diagnoses linked to clin-
ical care by addressing the following key questions:
 Is the online promotion and postal delivery of free
HIV self-test kits (with testing reminders) feasible
and acceptable?
 Will the offer of a single free HIV self-test at enrol-
ment lead to the confirmed diagnosis of prevalent
HIV infections and entry to standard HIV clinical
care?
 Among seronegative individuals at high risk of
acquiring HIV infection, will the offer of regular free
self-tests with testing reminders result in more rapid
confirmed diagnosis of an incident HIV infection
and entry in to standard HIV clinical care?
 What data can be generated to inform key
parameters for a cost effectiveness model?
Subsidiary objectives include: describing the usage and
acceptability of HIVST; determining if the offer of free
HIVST kits affects the overall frequency of HIV testing
and testing options utilised; assessment of post-test link-
age with counselling and treatment services; assessing
whether free HIVST kits affects the frequency of STI
screening or the frequency of condomless sex; investigat-
ing the impact of demographic, socio-economic, health-
related factors, and sexual risk behaviours on testing
behaviours.
Methods/design
Design
SELPHI is an ongoing open-label parallel group rando-
mised controlled trial with a two-stage simple random-
isation aiming to enrol 10,000 participants (Fig. 1).
Randomisation A takes place at enrolment, with partici-
pants randomly allocated (in a 3:2 ratio) to the offer of a
free baseline HIV self-test (BT) versus no offer of a free
baseline HIV self-test (nBT). An unequal allocation ratio
was chosen so that a majority of those agreeing to par-
ticipate would receive a free self-test and to increase the
number of participants eligible for Randomisation B.
This second randomisation occurs at month 3 after
enrolment, and is more restrictive, being open only to
participants who were initially allocated to the BT group
in Randomisation A who complete the 3-month survey,
and who meet additional eligibility criteria, including be-
ing at high risk of incident HIV infection, assessed at
3 months. Eligible participants are randomised (1:1) to
receive the offer of regular (immediately and every 3
months thereafter) free HIV self-tests + testing re-
minders (RT) versus no such offer (nRT).
Primary outcome measure
The primary outcome for both randomisations is a
laboratory-confirmed HIV diagnosis, with date of diag-
nosis defined as the date of the first confirmatory test at
clinic. This key feature of SELPHI distinguishes it from
other randomised trials of HIVST.
Inclusion criteria
The inclusion criteria for SELPHI are broad in order to
maximise generalisability and are detailed in Table 1. The
residency restriction was a requirement of the funding
body. The consent for linkage to Public Health Databases
was essential as this is the main mechanism for determin-
ing the trial primary endpoints. The criterion in Random-
isation B of reporting at least one male condomless anal
sex act in the previous 3 months is intended to identify in-
dividuals at higher risk of acquiring HIV infection.
Study procedures
Recruitment and enrolment
SELPHI is an internet-based study using advertising
campaigns, placed on social networking websites and via
mobile phone applications designed to facilitate sexual
and social contact, to recruit participants for example
Facebook, Grindr, Hornet and community webpages.
Advertising is tailored to attract individuals from a broad
spectrum of MSM and trans people. Depending on the
advertising platform, messages take a number of forms:
“Broadcast Message” (sent directly to an individual’s
“inbox” in a particular app), “Pop-up Message” (pop-up
message which shows when an individual logs in to an
app), “Banner Ad” (shown on screen within an app or
website whilst a user is online). Examples of adverts are
shown in Fig. 2.
Participants are directed to the study registration page
where they are asked to complete a two-stage sign-up
process. All data are collected in electronic surveys hosted
by Demographix Ltd. The first stage provides information
about the study, assesses eligibility, obtains informed con-
sent, and requests an email address. An email is immedi-
ately sent to this address with a link to complete the
second stage of the process. This serves to validate the
email address provided by the participant, which is the
means of all future communication throughout the trial.
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In the second stage, further demographic and behavioural
characteristics are collected (summarised in Table 2).
Once the second stage is completed, participants are ran-
domised and allocated to receive a free baseline HIV
self-test (BT) or no free baseline test (nBT). Those allo-
cated to BT are directed to provide postal details for ship-
ment of the test kit; those allocated to nBT are directed to
an area on the study website (www.selphi.org) which pro-
vides information on how to obtain an HIV test in other
ways (e.g. local GUM clinics).
HIV self-testing kits
In the UK, HIVST was legalised in April 2014, and the
first CE marked kit (BioSURE® HIV Self Test, BioSURE,
United Kingdom) was released to the UK market in
April 2015. The BioSURE® HIV Self Test kit is classed as
a 2nd generation test (an antibody immunoassay detect-
ing HIV 1/2 antibodies from approximately 28 days after
infection), uses a whole blood sample and retail at £30–
£35. Further HIVST kits have subsequently obtained a
CE mark, including the blood based INSTI HIV Self
Fig. 1 Trial Schema
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Test (bioLytical Laboratories, Canada) which detects
anti-HIV-1 IgM antibodies as well as anti-HIV-1 IgG (a
3rd generation assay) and can detect HIV infection from
21 days after infection.
The HIV self-testing kit used in the study is the Bio-
SURE® HIV Self Test which is CE marked and licensed
for use in the UK. The test comprises a paper test strip
inside a plastic barrel, and is performed by mixing a
small drop of blood with test reagents contained in the
buffer pot where the liquid reagents are absorbed by the
paper strip. When the test is completed, two lines can
appear on the paper test strip. The upper line (the Con-
trol line) becomes visible if the test has been performed
correctly. The lower line (the Test line) becomes visible
if the applied sample contains sufficient antibodies to
HIV. The BioSURE® HIV self-test product insert esti-
mates its sensitivity to be 99.7% (95% CI 98.9–100).
In addition to written information provided with the
test kit, an online video providing instructions on kit use
(produced by BioSURE) is also promoted to participants
on joining the study and is available on the study website
(https://youtu.be/N4CAqsmN_6g).
Follow up
All follow-up in SELPHI is conducted via online surveys
which are only accessible using a unique personalised URL
sent to participants by email. The content of surveys de-
pends on the randomised allocation and uses conditional
Fig. 2 Advertising Samples
Table 1 Inclusion criteria
Randomisation A Randomisation B
• Male (including trans men)
and trans women
• Aged ≥16 years old
• Resident in England or Wales
• Not known to be HIV-positive
• Has ever had anal sex with a
man
• Willing to provide name, date of
birth, and a valid email address
• Consent for linkage to
surveillance and clinic databases
held by Public Health England
• Not previously randomised to
the study
• Allocated to baseline self-test (BT)
in Randomisation A
• Completes the first survey after 3-
months and:
ο Reports using self-test sent at
baseline
ο Remains HIV-negative
ο Reports condomless anal sex with
≥1 male partners in previous
3 months
ο Interested in using HIV self-test
kits in the future
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branching to create a customised path through the survey
based on responses to earlier questions.
Following entry to Randomisation A participants rando-
mised to BT are asked to provide a postal address for ship-
ment of their free HIVST (which arrives within 5–7 days).
Participants in the BT arm receive an invite to complete a
short follow-up 2 weeks later, primarily to confirm that they
received the HIVST and to ascertain if they have used it.
Participants in the control arm are provided with signposts
to allow them to access other options for HIV testing. All
participants in Randomisation A are followed up at
3 months in an online survey, asking about HIV tests (type
and number) conducted since baseline and the results of
these tests, STI testing and the number of sexual partners
since baseline. Questions are identical in the two groups,
except the BT group is also asked to rate their experiences
in receiving and using the HIVST. This survey also includes
questions which determine eligibility for Randomisation B
(refer to Table 2). Participants who do not enter Random-
isation B receive no further surveys apart from one at the
end of the study. Participants randomised to RT are imme-
diately informed that they can order a further free HIVST
now and every 3 months subsequently.
Participants in both arms (nRT and RT) of Randomisa-
tion B receive an invite to complete a survey every 3 months
until the end of the study. For those in the RT arm, both
the invitation and survey include a reminder to test and the
offer of another free HIVST kit. The process for obtaining a
kit is the same as the process at baseline; kits are not sent
automatically but the participant “orders” another kit if they
wish to. Participants are not obliged to order a kit every 3
months, if they choose not to receive another kit they will
continue to be offered kits three-monthly. Following every
kit order the participant will receive a 2-week follow-up as
with their first kit. Follow-up in Randomisation B will con-
tinue until the last participant randomised is followed-up
for 2 years. All participants who have not tested positive
during the study will be sent an email at the end of the
study inviting them to complete a final survey and to thank
them for their participation.
If a participant reports testing HIV positive at any point
during the study they are directed to resources where they
can access support (e.g. THT Direct 24-h Helpline) and
are no longer invited to complete any further follow-up
surveys.
Determination of primary outcomes
Primary outcomes will be identified by linking the per-
sonal identifiers collected in SELPHI to the national
(England and Wales) HIV surveillance database main-
tained by PHE, who are collaborators on the trial. Link-
age will be performed by a computer algorithm,
primarily based on date of birth and patient surname
(encoded to Soundex). Putative links will be confirmed
Table 2 Summary of variables collected on electronic surveys
Variable Patient
Group
Time point(s)
Age ALL Baseline
Soundex ALL Baseline
Postcode ALL Baseline
Country of Birth ALL Baseline
Length of residency in the UK ALL Baseline
Ethnicity ALL Baseline
Highest Educational Qualification ALL Baseline
Sexual Identity ALL Baseline
Timing of last HIV test ALL Baseline
Timing of last STI screen ALL Baseline
Number condomless anal intercourse
partners (last 3 months)
ALL Baseline
PrEP and PEP usage ALL Baseline
Confirmation of HIVST Kit receipt BT/RT 2-weeks post kit
shipment
BT 3-month post baseline
RT 3-monthly post
Randomisation B entry
Confirmation of HIVST Kit usage BT/RT 2-weeks post kit
shipment
BT 3-month post baseline
RT 3-monthly post
Randomisation B entry
Self-reported HIVST result BT/RT 2-weeks post kit
shipment
BT 3-month post baseline
RT 3-monthly post
Randomisation B entry
Kits receipt & usage experiences BT 3-month post baseline
RT 3-monthly post
Randomisation B entry
Timing of HIV tests in last 3 months
(not including HIVST)
BT/NBT 3-month post baseline
RT/NRT 3-monthly post
Randomisation B entry
Self-reported HIV positive test result
(from any other source)
BT/NBT 3-month post baseline
RT/NRT 3-monthly post
Randomisation B entry
Timing of STI tests in last 3 months BT/NBT 3-month post baseline
RT/NRT 3-monthly post
Randomisation B entry
Number condomless anal intercourse
partners (last 3 months)
BT/NBT 3-month post baseline
RT/NRT 3-monthly post
Randomisation B entry
Interest in future HIVST If available BT/NBT 3-month post baseline
Offer of another free HIVST RT Randomisation B Entry
RT 3-monthly post
Randomisation B entry
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manually by matching on common variables, including
geographical region, ethnicity, gender, and initials. On
confirmed matched cases, PHE will return information
on date of diagnosis, region of diagnosis, CD4 count and
viral load at diagnosis, whether participants have linked
to care and initiated treatment, and GUM clinic attend-
ance history. Furthermore, at each follow-up survey par-
ticipants are asked about any HIV tests taken and any
HIV-positive diagnoses. Consistency between this infor-
mation and that recorded in PHE databases will be
cross-checked. A self-reported diagnosis will not be ac-
cepted as a primary outcome if it cannot be matched to
a confirmatory test in the PHE database or from a local
clinic.
Patient and public involvement (PPI)
As per the NIHR INVOLVE guidelines, patient and pub-
lic involvement (PPI) was sought during the trial devel-
opment. PPI representatives from HIV i-Base, NAM and
other organisations are included in programme manage-
ment group and the trial management group. These
community members led the establishment of a study
specific Community Advisory Group (CAG) and devel-
oped other public involvement models. Patient and pub-
lic involvement was integrated throughout the study and
budgeted in the initial grant application. For example, it
informed the development of the trial design, protocol,
participant information and consent materials, surveys,
recruitment strategy and advertising materials. This in-
volvement notably expanded the entry criteria to include
transgender women, even though the original grant was
limited to gay and bisexual men. The change was driven
by the lack of specific research and access for this popu-
lation and the precedent of broader inclusion in other
prevention studies (for example with PrEP).
Ethical considerations
The potential adverse psychological consequences of a
reactive test result were considered during the process of
obtaining CE-marking for the BioSURE® self-test kit, but
the regulatory authorities were satisfied that benefit of an
individual knowing that they had HIV outweighed the small
risk of harm. A second potential adverse consequence is
that people who obtain a reactive test result might not
subsequently attend clinical services for confirmatory HIV
testing and therefore might not engage with care. Conse-
quently, participants who report a reactive HIV test result
in the study are directed to appropriate resources through
the study website. These include guidance on how to find
local GUM clinics and links to the Terrance Higgins Trust
(THT) Direct hotline and the NHS Direct service to assist
them in dealing with a new diagnosis and accessing con-
firmatory testing and HIV care services. There was exten-
sive discussion around whether the lower age limit should
be 18 years (standard age for consent for adult medical re-
search) or 16 years (the legal age for consent for consensual
sex). The latter age was chosen following consultation with
the SELPHI CAB and then the Ethics Committee that ap-
proved the protocol.
Identifiable and sensitive data are collected within the
trial, including questions on sexual behaviours, recre-
ational drug use and HIV status. In compliance with all
relevant legislation (including the Data Protection Act),
data are stored securely within appropriate systems oper-
ated by Demographix Ltd. and University College London
(Data Safe Haven) which meet the ISO27001 information
security standard as a minimum. In datasets provided to
PHE for the purposes of linkage, the minimum number of
data fields are transferred, forenames are redacted to ini-
tials and surnames are encoded to Soundex, a phonetic al-
gorithm which indexes names by sound as pronounced in
English. All personal identifiers are stripped from datasets
produced for statistical analyses.
Through patient and public involvement, it was de-
cided that describing the full complexity of the trial de-
sign would result in information overload and could
hinder recruitment. Potential participants are therefore
simply informed that they will be randomised to one or
more self-tests to which they are asked to consent, ra-
ther than explicit and separate consents for Randomisa-
tion A and Randomisation B.
Statistical analysis
The primary analyses will compare the randomised groups
as allocated (intention to treat, ITT) in terms of a con-
firmed HIV diagnosis. Specifically, the primary outcome
for Randomisation A is a confirmed HIV diagnosis within
3 months of the date of randomisation i.e. before the
3-month survey, which could influence testing behaviour
in the nBT group, is sent out. The difference between ran-
domised arms will be tested by a chi-squared test for com-
parison of proportions. Logistic regression analysis will be
used to explore the effect of other covariates and potential
interactions with randomisation arm. As the offer of a free
test at enrolment could theoretically also affect future test-
ing behaviour, a secondary survival analysis will examine
the time to confirmed diagnosis.
The primary outcome for Randomisation B (RT versus
nRT) is time to confirmed diagnosis of HIV from the
date of randomisation. The analysis includes information
on participants who do not experience the event, using
time-to-event methods. Ideally, we would describe the
interval from the time of acquisition of HIV infection
rather than randomisation, but this is not generally ob-
served. We note that the number and timing of endpoints
is a function both of underlying HIV incidence and the
interval between infection and diagnosis. If the self-testing
intervention affects the former this will induce a difference
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between the randomised groups, even if there is no impact
on diagnosis rates; although we cannot exclude the possi-
bility of such a mechanism we consider it to be unlikely.
The difference between randomised arms will be tested by
a log rank test, supplemented by Cox regression models
to examine the effect of covariates. The (administrative)
censoring date for participants who do not experience the
primary outcome will depend on the calendar date when
linkage to PHE datasets is performed (see Determination
of primary outcomes).
Sample size
The standard approach to sample size is to first pre-specify
key parameters, including the desired statistical power, and
then calculate the sample size. However, this approach was
not practicable as we were constrained by the budget for
the HIVST kits and as certain key parameters were highly
uncertain. Instead, for the pre-determined sample size of
10,000 we have estimated the statistical power over plaus-
ible ranges of values for these parameters.
The power of the analysis of Randomisation A is a func-
tion of underlying HIV seroprevalence and the proportion
of seropositive participants in the BT and nBT groups di-
agnosed within 3 months. We considered HIV seropreva-
lence values between 1.5 and 2.5%, based on HIV self-
sampling in the UK, [25] and proportions diagnosed be-
tween 20 and 50% in the nBT group and between 50 and
80% in the BT group. Table 3 shows the statistical power
for various combinations of these proportions when HIV
seroprevalence is 2.0%. In general, power is acceptably
high when the difference between the BT and nBT groups
is at least 30% (in absolute terms).
We have assumed that 3,000 participants will enter Ran-
domisation B i.e. 50% of those enrolled in the BT group
meet the additional eligibility criteria. We used simulation
to estimate the statistical power for this randomisation as
an analytical approach was not tractable. As repeat HIV
self-tests can only affect the time to diagnosis of partici-
pants who become infected during the study, a key param-
eter is the underlying HIV incidence rate. Values between
1.5 and 3.0 per 100 person-years (PY) were explored,
based on estimates among MSM attending GUM clinics
in England. Another important parameter is the interval
between infection and diagnosis in the nRT group: this
was assumed to follow a Weibull distribution with a shape
parameter of 0.4 (to produce a higher initial rate of detec-
tion of infection) and a median ranging from 1.0 to
2.5 years [26, 27]. The corresponding interval in the RT
group was determined by the uptake of the offer of repeat
tests and the proportion linking to care following a react-
ive self-test. Table 4 shows the statistical power and other
analytical outputs as a function of key parameters.
Discussion
Globally, SELPHI is the largest RCT evaluating the offer
of free HIVST kits via the internet, and has uniquely
been designed to assess the impact of this intervention
on HIV diagnosis with linkage to clinical care and thus
access to early ART.
SELPHI was challenging to design and the results will
also need to be interpreted carefully. First, any future
offer of free HIVST kits within a health services context
will be a direct offer rather than the possibility (deter-
mined by randomisation) of receiving a test and agreeing
to complete regular follow-up questionnaires. This raises
concerns about generalisability, particularly if some par-
ticipants joined the trial for altruistic motives, and may
Table 3 Power (%) to detect a difference between BT and nBT
groups in Randomisation A
Diagnosis rate
in nBT group (%)
Diagnosis rate in BT group (%)
50 60 70 80
20 91 99 100 100
30 53 83 96 99
40 16 45 75 92
50 5 14 39 68
Power to detect a difference at 2α = 0.05 by chi-squared test
Assumes seroprevalence rate = 2%
Table 4 Power to detect a difference between RT and nRT
groups in Randomisation B
HIV
Incidence
(per 100 PY)
Median time
to diagnosis
(years) in nRT
group
Power
(%)
Estimated
HIV
infections
per group
Median
number
HIV
diagnoses
(nRT/RT)
Median
hazard
ratio
(RT versus
nRT)
1.5 1.0 56 53 24/40 1.73
1.5 72 53 21/40 1.91
2.0 82 53 19/40 2.08
2.5 87 53 18/40 2.21
2.0 1.0 75 71 30/53 1.70
1.5 83 71 28/52 1.94
2.0 91 71 26/52 2.08
2.5 93 71 24/51 2.20
2.5 1.0 83 89 38/66 1.73
1.5 93 89 34/65 1.92
2.0 96 89 32/65 2.09
2.5 98 89 30/64 2.25
3.0 1.0 89 107 46/78 1.74
1.5 96 107 41/77 1.92
2.0 98 107 38/77 2.09
2.5 99 107 36/77 2.23
Power to detect a difference at 2α = 0.05 by log-rank test
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affect recruitment to the trial, as a free HIV-test is not
guaranteed. Secondly, results will need to be interpreted
in the context of the current “standard of care”. When
the trial was initially being designed HIVST was illegal
in the UK, whereas the BioSURE kits were commercially
available when SELPHI launched in February 2017. The
study objectives therefore needed to be defined carefully
i.e. the effectiveness of offering free tests rather than of-
fering tests per se. A related issue is the impact of other
self-sampling and self-testing initiatives from other orga-
nisations in the UK.
Another moot design point was whether sending testing
reminders should be an intrinsic part of the intervention or
whether this should be considered as a separate interven-
tion. We considered a factorial design but eventually de-
cided that the HIVST kits and testing reminders should
constitute a single “package”, reflecting the likely promotion
of HIVST kits during implementation and to maximise the
chance of demonstrating an effect. A residual concern is
that the regular 3-monthly questionnaires will act as a re-
minder for participants in the nRT group to seek an HIV
test and reduce the difference between the groups. How-
ever, we expect that a large proportion of participants in
this group will opt out of receiving emails or ignore the
follow-up surveys. This highlights the importance of deter-
mining the study primary endpoint from an independent
national surveillance database to mitigate potential selective
survey completion bias. A similar linkage to the PHE na-
tional dataset has been conducted to identify additional in-
fections in the long-term follow-up of participants in the
PROUD trial of HIV pre-exposure prophylaxis [28]. Re-
assuringly, of the 32 participants who were diagnosed in
one of the PROUD clinics, only 1 (3%) was not identified in
the national surveillance database [29]. The sample size cal-
culation for SELPHI factored in a linkage failure rate of
10%. Another consideration is the delay in the centralisa-
tion and reconciliation of reports of HIV diagnoses from
clinics and laboratories across the country, and a finalised
dataset for a given calendar year is usually not available
until June of the following year.
SELPHI is expected to complete in 2020 although the re-
sults of Randomisation A should be available earlier than
this. As well as the main randomised comparisons, we are
undertaking qualitative sub-studies of SELPHI participants,
process evaluation and developing cost-effectiveness models
which will be informed by the results of the trial.
With expanded prevention and treatment options avail-
able for people living with HIV, the need for testing and
diagnosis is more important than ever. The reality of
shrinking NHS resources and radical cuts and changes to
sexual health service provision will require increased
innovation with cost saving services such as e-health and
postal services. This shift will increase the relevance of re-
sults from this trial.
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